Civica plans shake-up of insulin sector with low-cost biosimilars
pharmaphorum
MARCH 3, 2022
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. Cheaper options are meanwhile becoming available.
Let's personalize your content